ӳ��ý

Publications

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.

Ruiz-Torres DA, Bryan ME, Hirayama S, et al. Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer. medRxiv : the preprint server for health sciences. 2024. doi:10.1101/2024.09.10.24313432

Manipulating cell fate through reprogramming: approaches and applications.

Yagi M, Horng JE, Hochedlinger K. Manipulating cell fate through reprogramming: approaches and applications. Development (Cambridge, England). 2024;151(19). doi:10.1242/dev.203090

A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.

Huffman BM, Rahma OE, Tyan K, et al. A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer. Cancer immunology research. 2024. doi:10.1158/2326-6066.CIR-23-1027

Steroid Hormone Biosynthesis and Dietary Related Metabolites Associated with Excessive Daytime Sleepiness.

Faquih T, Potts K, Yu B, et al. Steroid Hormone Biosynthesis and Dietary Related Metabolites Associated with Excessive Daytime Sleepiness. medRxiv : the preprint server for health sciences. 2024. doi:10.1101/2024.09.12.24313561

Cross-EHR validation of antidepressant response algorithm and links with genetics of psychiatric traits.

Sealock JM, Tubbs JD, Lake AM, Straub P, Smoller JW, Davis LK. Cross-EHR validation of antidepressant response algorithm and links with genetics of psychiatric traits. medRxiv : the preprint server for health sciences. 2024. doi:10.1101/2024.09.11.24313478

Publisher Correction: Statistically and functionally fine-mapped blood eQTLs and pQTLs from 1,405 humans reveal distinct regulation patterns and disease relevance.

Wang QS, Hasegawa T, Namkoong H, et al. Publisher Correction: Statistically and functionally fine-mapped blood eQTLs and pQTLs from 1,405 humans reveal distinct regulation patterns and disease relevance. Nature genetics. 2024. doi:10.1038/s41588-024-01959-5

Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases.

van Karnebeek CDM, O’Donnell-Luria A, Baynam G, et al. Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases. Orphanet journal of rare diseases. 2024;19(1):357. doi:10.1186/s13023-024-03361-0

Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies.

Khanmohammadi S, Habibzadeh A, Kamrul-Hasan ABM, Schuermans A, Kuchay MS. Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies. Diabetic medicine : a journal of the British Diabetic Association. 2024:e15437. doi:10.1111/dme.15437

Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues.

Hassan MM, Der Li Y, Ma MW, et al. Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues. European journal of medicinal chemistry. 2024;279:116904. doi:10.1016/j.ejmech.2024.116904

Circulating tumor DNA predicts venous thromboembolism in patients with cancers.

Ma S, Jiang JY, Kim RB, et al. Circulating tumor DNA predicts venous thromboembolism in patients with cancers. Journal of thrombosis and haemostasis : JTH. 2024. doi:10.1016/j.jtha.2024.09.009